Case report: Long-term clinical benefit of pyrotinib therapy following trastuzumab resistance in HER2-amplification recurrent mucinous ovarian carcinoma

Fang, Xiangming; Mou, Haibo; Ying, Xinxin; Hou, Xuehua; Luo, Wei; Wu, Ying; Yan, Naimeng; Guo, Lijie; Liao, Qin

doi:10.3389/fonc.2022.1024677

Cited by 3 publications

(2 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Adequate diagnosis of breast cancer metastases and HER2 status is necessary for determining the appropriate treatment strategy. Anti-HER2 therapy has been demonstrated to be an effective strategy for the treatment of HER2-positive breast cancer [42]. HER2 overexpression has also been associated with ovary, endometrium, fallopian tube, gastric and prostate cancers [43][44][45].…”

Section: Discussionmentioning

confidence: 99%

Efficient Convolution Network to Assist Breast Cancer Diagnosis and Target Therapy

Wang

Chu

Muzakky

et al. 2023

Cancers

View full text Add to dashboard Cite

Breast cancer is the leading cause of cancer-related deaths among women worldwide, and early detection and treatment has been shown to significantly reduce fatality rates from severe illness. Moreover, determination of the human epidermal growth factor receptor-2 (HER2) gene amplification by Fluorescence in situ hybridization (FISH) and Dual in situ hybridization (DISH) is critical for the selection of appropriate breast cancer patients for HER2-targeted therapy. However, visual examination of microscopy is time-consuming, subjective and poorly reproducible due to high inter-observer variability among pathologists and cytopathologists. The lack of consistency in identifying carcinoma-like nuclei has led to divergences in the calculation of sensitivity and specificity. This manuscript introduces a highly efficient deep learning method with low computing cost. The experimental results demonstrate that the proposed framework achieves high precision and recall on three essential clinical applications, including breast cancer diagnosis and human epidermal receptor factor 2 (HER2) amplification detection on FISH and DISH slides for HER2 target therapy. Furthermore, the proposed method outperforms the majority of the benchmark methods in terms of IoU by a significant margin (p<0.001) on three essential clinical applications. Importantly, run time analysis shows that the proposed method obtains excellent segmentation results with notably reduced time for Artificial intelligence (AI) training (16.93%), AI inference (17.25%) and memory usage (18.52%), making the proposed framework feasible for practical clinical usage.

show abstract

Section: Discussionmentioning

confidence: 99%

Efficient Convolution Network to Assist Breast Cancer Diagnosis and Target Therapy

Wang

Chu

Muzakky

et al. 2023

Cancers

View full text Add to dashboard Cite

show abstract

“…16,17 Notably, bladder cancer patients with an ERBB2 mutation showed a favorable response to trastuzumab. 18,19 However, there are limited reports on the use of trastuzumab in renal pelvis carcinoma.…”

Section: Introductionmentioning

confidence: 99%

Advanced renal pelvis carcinoma patient with an ERBB2 insertion mutation: a case report

Shang,

Lou,

Yin

et al. 2023

J Int Med Res

View full text Add to dashboard Cite

The prognosis of renal pelvis cancer is poor and therapeutic options are limited, especially for patients with advanced disease. In this report, we present a case of advanced renal pelvis carcinoma in a male patient in his 60s, characterized by an activating mutation in ERBB2. Clinical evaluation resulted in a pathological diagnosis of renal pelvis carcinoma with liver metastasis. Immunohistochemistry staining results suggested that CK, P63, and PAX8 were positively expressed, while Sy, CK7, CK20, S100, PAX8, and HEP1 were negatively expressed. Furthermore, next-generation sequencing results showed an activating mutation in the ERBB2 gene. The patient initially received a trastuzumab-based combination therapy, which led to a significant reduction in ERBB2 mutation frequency and a stable condition after three treatment cycles. However, following continuous treatment for 4 months, the patient developed drug resistance that resulted in disease relapse. Subsequently, the patient received apatinib treatment, but the therapeutic response was not satisfactory. The patient’s condition underwent rapid deterioration and he ultimately succumbed to the disease. This case underscores the potential benefit of trastuzumab for treating ERBB2-mutated advanced renal pelvis cancer, but further highlights that overcoming drug resistance remains a crucial challenge for long-term efficacy.

show abstract

Pertuzumab/trastuzumab

2023

Reactions Weekly

View full text Add to dashboard Cite

Case report: Long-term clinical benefit of pyrotinib therapy following trastuzumab resistance in HER2-amplification recurrent mucinous ovarian carcinoma

Cited by 3 publications

References 36 publications

Efficient Convolution Network to Assist Breast Cancer Diagnosis and Target Therapy

Efficient Convolution Network to Assist Breast Cancer Diagnosis and Target Therapy

Advanced renal pelvis carcinoma patient with an ERBB2 insertion mutation: a case report

Pertuzumab/trastuzumab

Contact Info

Product

Resources

About